3'-(5-amino-2-chloro-4-fluoro-3-methylbenzamido)-N,N-dimethyl-4'-(4-methyl-piperazin-1-yl)-[1,1'-biphenyl]-4-carboxamide

ID: ALA4868755

PubChem CID: 156357381

Max Phase: Preclinical

Molecular Formula: C28H31ClFN5O2

Molecular Weight: 524.04

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: Cc1c(F)c(N)cc(C(=O)Nc2cc(-c3ccc(C(=O)N(C)C)cc3)ccc2N2CCN(C)CC2)c1Cl

Standard InChI: InChI=1S/C28H31ClFN5O2/c1-17-25(29)21(16-22(31)26(17)30)27(36)32-23-15-20(9-10-24(23)35-13-11-34(4)12-14-35)18-5-7-19(8-6-18)28(37)33(2)3/h5-10,15-16H,11-14,31H2,1-4H3,(H,32,36)

Standard InChI Key: TYHLFPRXEUVIDJ-UHFFFAOYSA-N

Molfile:

 
     RDKit          2D

 37 40  0  0  0  0  0  0  0  0999 V2000
    9.2632   -6.4135    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5577   -6.0029    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5607   -5.1857    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2733   -4.7792    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9788   -5.1939    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9717   -6.0111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2562   -7.2348    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9617   -7.6454    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9587   -8.4626    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2461   -8.8691    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5406   -8.4544    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5477   -7.6372    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2763   -3.9620    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9848   -3.5596    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    9.2431   -9.6863    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.9486  -10.0969    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.9457  -10.9141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2331  -11.3207    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.5275  -10.9059    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.5346  -10.0888    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.2301  -12.1378    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3727   -8.4707    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0782   -8.8813    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.0753   -9.6985    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.7808  -10.1132    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.4893   -9.7067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.4923   -8.8895    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.7867   -8.4789    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.3798   -7.6536    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.6642   -8.8732    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.7737  -10.9304    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.1948  -10.1214    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   11.3627  -10.1051    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   14.2049   -8.4871    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.5707   -3.5496    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.5751   -2.7325    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.8609   -3.9545    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  1  6  2  0
  7  8  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
  7 12  2  0
  1  7  1  0
 13 14  2  0
  4 13  1  0
 15 16  1  0
 16 17  1  0
 17 18  1  0
 18 19  1  0
 19 20  1  0
 15 20  1  0
 18 21  1  0
 10 15  1  0
 22 23  1  0
 23 24  1  0
 24 25  2  0
 25 26  1  0
 26 27  2  0
 27 28  1  0
 23 28  2  0
 22 29  2  0
 22 30  1  0
 25 31  1  0
 26 32  1  0
 24 33  1  0
 27 34  1  0
  9 30  1  0
 13 35  1  0
 35 36  1  0
 35 37  1  0
M  END

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Unknown	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 524.04	Molecular Weight (Monoisotopic): 523.2150	AlogP: 4.74	#Rotatable Bonds: 5
Polar Surface Area: 81.91	Molecular Species: NEUTRAL	HBA: 5	HBD: 2
#RO5 Violations: 1	HBA (Lipinski): 7	HBD (Lipinski): 3	#RO5 Violations (Lipinski): 1
CX Acidic pKa: ┄	CX Basic pKa: 7.60	CX LogP: 4.40	CX LogD: 3.98
Aromatic Rings: 3	Heavy Atoms: 37	QED Weighted: 0.47	Np Likeness Score: -1.42

References

1. Chen W, Chen X, Li D, Wang X, Long G, Jiang Z, You Q, Guo X.. (2021) Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity., 223 [PMID:34225179] [10.1016/j.ejmech.2021.113677]
2. Karatas, Hacer H, Townsend, Elizabeth C EC, Bernard, Denzil D, Dou, Yali Y and Wang, Shaomeng S. 2010-07-22 Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. [PMID:20575550]
3. Bolshan, Yuri Y and 16 more authors. 2013-03-14 Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction. [PMID:24900672]
4. Getlik, Matthäus M and 17 more authors. 2016-03-24 Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1). [PMID:26958703]
5. Li, Dong-Dong DD and 9 more authors. 2016-08-08 Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5. [PMID:27116709]
6. Li, Dong-Dong DD and 8 more authors. 2016-11-29 High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity. [PMID:27598236]
7. Li, Dong-Dong DD and 5 more authors. 2016-11-15 Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. [PMID:27720555]
8. Wang, Feng F and 17 more authors. 2018-07-12 Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design. [PMID:29889518]
9. Ye, Xiaoqing X and 11 more authors. 2019-02-15 The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening. [PMID:30626558]
10. Tian, Jianhua and 24 more authors. 2020-01-23 Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core. [PMID:31858797]
11. Chacón Simon, Selena and 14 more authors. 2020-04-23 Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design. [PMID:32223236]

3'-(5-amino-2-chloro-4-fluoro-3-methylbenzamido)-N,N-dimethyl-4'-(4-methyl-piperazin-1-yl)-[1,1'-biphenyl]-4-carboxamide

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source